Softhale is a Belgium-based pharmaceutical company specializing in the development of inhalable therapeutics using its proprietary Soft Mist Inhaler (SMI) technology. The company focuses on treating chronic respiratory diseases by delivering liquid drug formulations directly to the lungs with superior clinical performance. Softhale's SMI device is propellant-free and purely mechanical, offering a highly efficient and cost-optimized solution for pharmaceutical development and approval processes. The company's business model revolves around leveraging its differentiated technology to create pharmaceutical products that improve patient outcomes. Softhale serves the respiratory healthcare market, targeting both branded and generic product segments. Revenue is generated through the development and commercialization of these advanced inhalation therapies.

Keywords: inhalable therapeutics, Soft Mist Inhaler, respiratory diseases, chronic airflow limitations, propellant-free, liquid drug formulations, pharmaceutical development, clinical performance, cost-optimized, Belgium-based.